 CAMBRIDGE, Mass., June 3, 2021 PRNewswire -- Akebia Therapeutics, Inc. Nasdaq: AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association European Dialysis and Transplant Association ERA-EDTA Virtual Congress 2021, to be held June 5 - June 8, 2021. 